ACADIA Pharmaceuticals (ACAD) Projected to Post Quarterly Earnings on Wednesday

ACADIA Pharmaceuticals (NASDAQ:ACAD) is expected to be issuing its Q2 2025 quarterly earnings data after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of $0.14 per share and revenue of $263.07 million for the quarter. ACADIA Pharmaceuticals has set its FY 2025 guidance at EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.01. The business had revenue of $244.32 million during the quarter, compared to the consensus estimate of $239.32 million. ACADIA Pharmaceuticals had a return on equity of 17.46% and a net margin of 22.97%. The firm’s quarterly revenue was up 18.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.10 EPS. On average, analysts expect ACADIA Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ACADIA Pharmaceuticals Stock Performance

Shares of ACADIA Pharmaceuticals stock opened at $23.53 on Monday. The firm has a 50-day moving average of $22.18 and a 200-day moving average of $19.06. The stock has a market cap of $3.94 billion, a PE ratio of 17.18, a PEG ratio of 6.54 and a beta of 0.70. ACADIA Pharmaceuticals has a 52-week low of $13.40 and a 52-week high of $25.23.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, June 26th. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, June 26th. Wall Street Zen upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, May 21st. Deutsche Bank Aktiengesellschaft upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the company from $20.00 to $35.00 in a research note on Wednesday, May 21st. Finally, Morgan Stanley set a $24.00 target price on ACADIA Pharmaceuticals and gave the company an “equal weight” rating in a research report on Tuesday, May 20th. Six analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $28.13.

Insider Buying and Selling

In related news, EVP Mark C. Schneyer sold 2,000 shares of the company’s stock in a transaction on Friday, May 16th. The stock was sold at an average price of $25.00, for a total transaction of $50,000.00. Following the completion of the sale, the executive vice president directly owned 62,130 shares in the company, valued at $1,553,250. This represents a 3.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Laura Brege sold 14,446 shares of the stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $21.78, for a total transaction of $314,633.88. Following the completion of the transaction, the director directly owned 15,095 shares of the company’s stock, valued at $328,769.10. This trade represents a 48.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 20,446 shares of company stock worth $454,634 in the last ninety days. 28.30% of the stock is owned by insiders.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ACAD. Empowered Funds LLC bought a new position in ACADIA Pharmaceuticals in the first quarter valued at about $186,000. AQR Capital Management LLC raised its holdings in ACADIA Pharmaceuticals by 3.8% in the 1st quarter. AQR Capital Management LLC now owns 67,672 shares of the biopharmaceutical company’s stock valued at $1,124,000 after buying an additional 2,492 shares during the last quarter. Intech Investment Management LLC raised its holdings in ACADIA Pharmaceuticals by 45.6% in the 1st quarter. Intech Investment Management LLC now owns 75,872 shares of the biopharmaceutical company’s stock valued at $1,260,000 after buying an additional 23,766 shares during the last quarter. Royal Bank of Canada raised its holdings in ACADIA Pharmaceuticals by 74.4% in the 1st quarter. Royal Bank of Canada now owns 80,528 shares of the biopharmaceutical company’s stock valued at $1,338,000 after buying an additional 34,352 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in ACADIA Pharmaceuticals by 7.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 89,952 shares of the biopharmaceutical company’s stock valued at $1,498,000 after buying an additional 6,303 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.